Furthermore, targeting CSF‐1R has been proven effective on haematopoietic malignancies, such as multiple myeloma, chronic lymphocytic leukaemia (CLL) and a subset of AML.19, 20, 21, 22, 23. Here, CSF1R is linked to acute myeloid leukemia.